Search results
Results from the WOW.Com Content Network
[3] [4] In some plant families (of the order Caryophyllales), l-DOPA is the central precursor of a biosynthetic pathway that produces a class of pigments called betalains. [5] l-DOPA can be manufactured and in its pure form is sold as a drug with the INN Tooltip International Nonproprietary Name levodopa. Trade names include Sinemet, Pharmacopa ...
Levodopa crosses the protective blood–brain barrier, whereas dopamine itself cannot. [3] [4] Thus, levodopa is used to increase dopamine concentrations in the treatment of Parkinson's disease, Parkinsonism, dopamine-responsive dystonia and Parkinson-plus syndrome. The therapeutic efficacy is different for different kinds of symptoms.
Levodopa (L-DOPA), a prodrug of dopamine which is used to treat Parkinson's disease and certain other conditions. A neurotransmitter prodrug, or neurotransmitter precursor, is a drug that acts as a prodrug of a neurotransmitter. A variety of neurotransmitter prodrugs have been developed and used in medicine.
DopAmide, or L-DopAmide, is a synthetic levodopa (L-DOPA) analogue that can serve as a levodopa and dopamine prodrug and is of potential interest in the treatment of Parkinson's disease. [ 1 ] [ 2 ] [ 3 ] DopAmide has an amide rather than the carboxyl group of L -DOPA, [ 2 ] [ 3 ] which imparts greater water solubility .
Monoamine precursors are precursors of monoamines and monoamine neurotransmitters in the body. [ 1 ] [ 2 ] The amino acids L -tryptophan and L -5-hydroxytryptophan (5-HTP; oxitriptan) are precursors of serotonin and melatonin , while the amino acids L -phenylalanine , L -tyrosine , and L -DOPA (levodopa) are precursors of dopamine , epinephrine ...
XP-21279 is a sustained-release levodopa (L-DOPA) prodrug and hence a dopamine precursor and non-selective dopamine receptor agonist which was under development for the treatment of Parkinson's disease. [4] [1] [3] It is taken by mouth. [1] [2] [3]
New data showing Zolgensma’s substantial benefits for presymptomatic children made the drug cost-effective at prices up to $1.9 million by one benchmark and up to $2.1 million by another, it said.
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is an organic compound. It is classified as a tetrahydropyridine . It is of interest as a precursor to the monoaminergic neurotoxin MPP + , which causes permanent symptoms of Parkinson's disease by destroying dopaminergic neurons in the substantia nigra of the brain .